Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04746924
Recruitment Status : Recruiting
First Posted : February 10, 2021
Last Update Posted : November 3, 2021
Sponsor:
Information provided by (Responsible Party):
BeiGene

Brief Summary:
The purpose of the study is to compare progression-free survival (PFS) between Arm A (ociperlimab in combination with tislelizumab) and Arm B (pembrolizumab in combination with placebo) as assessed by investigators according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) and to compare overall survival (OS) between Arm A and Arm B.

Condition or disease Intervention/treatment Phase
Non-small Cell Lung Cancer NSCLC Drug: Tislelizumab Drug: Ociperlimab Drug: Pembrolizumab Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 605 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer
Actual Study Start Date : June 8, 2021
Estimated Primary Completion Date : November 2024
Estimated Study Completion Date : March 2025

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Arm A: Tislelizumab plus Ociperlimab
Participants will receive tislelizumab 200 milligrams (mg) intravenously followed by ociperlimab 900 mg intravenously once every 3 weeks.
Drug: Tislelizumab
Tislelizumab is a monoclonal antibody formulated for intravenous injection.
Other Name: BGB-A317

Drug: Ociperlimab
Ociperlimab is a monoclonal antibody formulated for intravenous injection.
Other Name: BGB-A1217

Active Comparator: Arm B: Pembrolizumab plus Placebo
Participants will receive pembrolizumab 200 mg intravenously followed by placebo intravenously once every 3 weeks.
Drug: Pembrolizumab
Pembrolizumab is a monoclonal antibody formulated for intravenous injection.
Other Name: KEYTRUDA

Drug: Placebo
Placebo infusions will consist of a sterile, normal saline solution.

Placebo Comparator: Arm C: Tislelizumab plus Placebo
Participants will receive tislelizumab 200 mg intravenously followed by placebo intravenously once every 3 weeks.
Drug: Tislelizumab
Tislelizumab is a monoclonal antibody formulated for intravenous injection.
Other Name: BGB-A317

Drug: Placebo
Placebo infusions will consist of a sterile, normal saline solution.




Primary Outcome Measures :
  1. Progression-free Survival (PFS) As Assessed By Investigators [ Time Frame: Up to approximately 39 months ]
    PFS will be defined as the time from the date of randomization to the date of the first objectively documented tumor progression per RECIST v1.1, or death, whichever occurs first.

  2. Overall Survival (OS) As Assessed By Investigators [ Time Frame: Up to approximately 39 months ]
    OS will be defined as the time from the date of randomization to the date of death due to any cause.


Secondary Outcome Measures :
  1. PFS As Assessed By A Blinded Independent Review Committee [ Time Frame: Up to approximately 39 months ]
    PFS will be defined as the time from the date of randomization to the date of the first objectively documented tumor progression per RECIST v1.1, or death, whichever occurs first.

  2. Overall Response Rate (ORR) As Assessed By Investigators [ Time Frame: Up to approximately 39 months ]
    ORR will be defined as the proportion of participants with a documented, confirmed complete response or partial response per RECIST v1.1.

  3. Duration Of Response (DOR) As Assessed By Investigators [ Time Frame: Up to approximately 39 months ]
    DOR will be defined as the time from the first determination of an objective response per RECIST v1.1 until the first documentation of progression or death, whichever occurs first.

  4. Health-related Quality Of Life (HRQoL): European Organization For Research And Treatment Of Cancer Quality Of Life Questionnaire Core 30 (EORTC QLQ-C30) [ Time Frame: Within 7 days after last dose ]

    HRQoL will be assessed via patient-reported outcomes (PRO) using the EORTC QLQ-C30.

    The EORTC QLQ-C30 (Version 3) uses for the questions 1 to 28 a 4-point scale. The scale scores from 1 to 4: 1 ("Not at all"), 2 ("A little"), 3 ("Quite a bit") and 4 ("Very much"). Half points are not allowed. The range is 3. For the raw score, less points are considered to have a better outcome.

    The EORTC QLQ-C30 (Version 3) uses for the questions 29 and 30 a 7-points scale. The scale scores from 1 to 7: 1 ("very poor") to 7 ("excellent"). Half points are not allowed. The range is 6. First of all, raw score has to be calculated with mean values. Afterwards linear transformation is performed to be comparable. More points are considered to have a better outcome


  5. HRQoL: EORTC Lung Cancer Module Quality Of Life Questionnaire Lung Cancer 13 (QLQ-LC13) [ Time Frame: Within 7 days after last dose ]
    HRQoL will be assessed via PRO using the EORTC QLQ-LC13. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) A score of 1-4 will be administrated for each item in QLQ-LC13. The higher scores will indicate the worse outcomes.

  6. HRQoL: The 5 Level EuroQol 5 Dimension (EQ-5D-5L) Questionnaire [ Time Frame: Within 7 days after last dose ]
    HRQoL will be assessed via PRO using the EQ-5D-5L. EQ-5D-5L - Is the EuroQol 5D-5L a descriptive system that comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

  7. Time To Deterioration (TDD) [ Time Frame: Within 7 days after last dose ]
    TDD will be analyzed using the global health status of QLQ-C30 and will be defined as worsening scores for 2 consecutive assessments or 1 assessment followed by death from any cause.

  8. Number Of Participants Experiencing Adverse Events (AEs) [ Time Frame: 90 days (±14) after last dose ]
    The incidence and severity of AEs will be determined according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  1. Histologically or cytologically documented locally advanced or recurrent non-small cell lung cancer (NSCLC) that is not eligible for curative surgery and/or definitive radiotherapy with or without chemoradiotherapy, or metastatic-nonsquamous or squamous NSCLC.
  2. No prior systemic treatment for metastatic NSCLC.
  3. Agreement to provide archival tissue (formalin-fixed paraffin-embedded block containing tumor [preferred] or 6 to 15 freshly cut unstained slides) or fresh biopsy (if archival tissue is not available) for prospective central evaluation of programmed cell death ligand-1 (PD-L1) levels and retrospective analysis of other biomarkers.
  4. Tumors with PD-L1 tumor cell ≥ 50% expression as centrally determined.
  5. At least 1 measurable lesion as defined per RECIST v1.1.

Key Exclusion Criteria:

  1. Known sensitizing mutation in the epidermal growth factor receptor (EGFR) gene or an anaplastic lymphoma kinase fusion oncogene.
  2. Prior therapy with an anti-programmed cell death protein (anti-PD)-1, anti-PD-ligand (L)-1, anti-PD-ligand-2, anti-T-cell immunoglobulin and ITIM (anti-TIGIT) domain, or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways.
  3. Active leptomeningeal disease or uncontrolled, untreated brain metastasis.
  4. Active autoimmune diseases or history of autoimmune diseases that may relapse.
  5. Any active malignancy ≤ 2 years before randomization except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated curatively (for example, resected basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast).

Note: Other protocol defined Inclusion/Exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04746924


Contacts
Layout table for location contacts
Contact: BeiGene 1-877-828-5568 clinicaltrials@beigene.com

Locations
Show Show 206 study locations
Sponsors and Collaborators
BeiGene
Layout table for additonal information
Responsible Party: BeiGene
ClinicalTrials.gov Identifier: NCT04746924    
Other Study ID Numbers: AdvanTIG-302
BGB-A317-A1217-302 ( Other Identifier: BeiGene )
First Posted: February 10, 2021    Key Record Dates
Last Update Posted: November 3, 2021
Last Verified: November 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by BeiGene:
Locally Advanced
Unresectable
Metastatic
Tislelizumab
BGB-A317
Ociperlimab
BGB-A1217
Pembrolizumab
Anti-TIGIT
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Pembrolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents